This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study


Mamikonyan, Eugenia, Xie, Sharon X., Melvin, Emilie, Weintraub, Daniel


Movement Disorders: Official Journal Of The Movement Disorder Society, Volume: 30, No.: 7, Pages.: 912-918

Year of Publication



Mild cognitive impairment (MCI) in Parkinson’s disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal patch. The primary outcome measure was the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). Secondary outcomes included the Montreal Cognitive Assessment (MoCA), Dementia Rating Scale-2 (DRS-2), Neurotrax computerized cognitive battery, the Everyday Cognition Battery (ECB), and the Parkinson’s Disease Questionnaire (PDQ-8). Twenty-six participants (92.9%) completed both study phase assessments, and 23 (82.1%) completed both phases on study medication. The CGIC response rate demonstrated a trend effect in favor of rivastigmine (regression coefficient for interaction term in linear mixed-effects model = 0.44, F[df] = 3.01 [1, 24], P = 0.096). For secondary outcomes, a significant rivastigmine effect on the ECB (regression coefficient = -2.41, F[df] = 5.81 [1, 22.05], P = 0.03) was seen, but no treatment effect was found on any cognitive measures. Trend effects also occurred in favor of rivastigmine on the PDQ-8 (regression coefficient = 4.55, F[df] = 3.93 [1, 14. 79], P = 0.09) and the State Anxiety Inventory (regression coefficient = -1.24, F[df] = 3.17 [1, 33], P = 0.08). Rivastigmine in PD-MCI showed a trend effect for improvements on a global rating of cognition, disease-related health status, and anxiety severity, and significant improvement on a performance-based measure of cognitive abilities. © 2015 International Parkinson and Movement Disorder Society.; © 2015 International Parkinson and Movement Disorder Society.

Bibtex Citation

@article{Mamikonyan_2015, doi = {10.1002/mds.26236}, url = {}, year = 2015, month = {apr}, publisher = {Wiley-Blackwell}, volume = {30}, number = {7}, pages = {912--918}, author = {Eugenia Mamikonyan and Sharon X. Xie and Emilie Melvin and Daniel Weintraub}, title = {Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study}, journal = {Movement Disorders} }


administration & dosage, aged, cholinesterase inhibitor, cholinesterase inhibitors, class i, clinical trials randomized controlled, complications, doubleblind method, drug therapy, etiology, female, humans, male, middle aged, mild cognitive impairment, outcome assessment (health care), parkinson disease, parkinsons disease, pharmacology, rivastigmine

Countries of Study


Types of Dementia

Mild Cognitive Impairment (MCI), Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition, Depression and Anxiety

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime